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Introduction
Advances  in  genomic  technology  and  computational 
approaches have significantly changed our understanding 
of the non-random distribution of human genetic variants 
and its impact on disease susceptibility and variable drug 
response across human populations. A critical element of 
this success story has been the availability of large cohorts 
of  unrelated  individuals  and  families  willing  to  donate 
tissue  and  blood  samples  for  genetic  and  biochemical 
analysis.  Increasingly,  genomic  studies  are  being  con-
ducted among people from diverse cultural, linguistic and 
socio-economic backgrounds throughout the world. The 
global expansion of genomic research, combined with the 
rapid  evolution  of  scientific  knowledge  and  the  public 
health  need  to  translate  genomic  findings,  show  the 
impor  tance  of  continued  development  of  new,  effective 
approaches to the process of informed consent. Here, we 
use  national  and  inter  national  projects  to  illustrate  the 
growing  complexities  of  scientific  and  ethical  issues  in 
genomics  and  their  implications  for  informed  consent. 
Tailored approaches to the informed consent process need 
to address both the scientific and regulatory constraints of 
designing  and  implementing  genomic  research,  and  the 
experiences, knowledge and concerns of individuals and 
diverse communities invited to join genetic research projects.
Points to consider in tailoring informed consent to 
genetic research
National and international policies and guidelines address 
a broad range of issues regarding ethical conduct in genetic 
and genomic studies [1-6]. These policies and recommen-
dations, and legislation such as the US Genetic Nondis  cri-
mi  nation  Information  Act  (GINA)  of  2008  [7],  focus 
attention on topics ranging from the collection and storage 
of samples [8], data sharing for research purposes [9-11], 
protection of individual privacy [12-14], and the process 
and  documentation  of  informed  consent  [15-18].  Our 
objective  here  is  to  highlight  and  briefly  describe  the 
importance  of  ten  core  scientific,  cultural  and  social 
factors that are particularly relevant to designing ethically 
responsible approaches to informed consent in genomic 
research  involving  ethnically,  socio-economically  and 
linguistically diverse study populations globally (Table 1).
Abstract
Genomic science and associated technologies are 
facilitating an unprecedented rate of discovery of 
novel insights into the relationship between human 
genetic variation and health. The willingness of large 
numbers of individuals from different ethnic and 
cultural backgrounds to donate biological samples 
is one of the major factors behind the success of 
the ongoing genomic revolution. Although current 
informed consent documents and processes 
demonstrate a commitment to ensuring that study 
participants are well informed of the risks and 
benefits of participating in genomic studies, there 
continues to be a need to develop effective new 
approaches for adequately informing participants 
of the changing complexities of the scientific and 
ethical issues that arise in the conduct of genomics 
research. Examples of these complexities in genomic 
research include more widespread use of whole-
genome sequencing technologies, broad sharing of 
individual-level data, evolving information technology, 
the growing demand for the return of genetic results 
to participants, and changing attitudes about privacy 
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and socio-economic backgrounds. We highlight and 
briefly discuss the importance of ten core scientific, 
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to tailoring informed consent in genomic research, 
and we draw attention to the need for the informed 
consent document and process to be responsive to the 
evolving nature of genomic research.
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Protocols  for  genomic  research  differ  considerably 
depend  ing on the study aims, sample populations and the 
procedures,  risks  and  benefits  associated  with  the 
research. The particular study design and the relationship 
of investigators to individuals and communities involved 
in  the  project  have  implications  for  the  obligations  of 
researchers to study participants; this in turn influences 
the  substance  and  process  of  informed  consent.  For 
example, the International HapMap Project [19] involved 
the  collection  of  anonymized  samples  to  identify  and 
catalog  genetic  similarities  and  differences  in  human 
beings. Providing personal feedback to participants about 
genetic results in the HapMap project was therefore not a 
possibility.  In  contrast,  large-scale  medical  genotyping 
and sequencing research studies such as the pioneering 
National Institutes of Health (NIH) medical sequencing 
project  called  ClinSeq  [20,21],  which  is  designed  to 
investigate  how  to  do  genome  sequencing  in  clinical 
research, will provide genetic and clinical information to 
partici  pants.  To  accommodate  this  study  design,  the 
informed consent process for ClinSeq addresses complex 
issues regarding procedures for communicating infor  ma-
tion and the implications for individuals who receive the 
results.
The informed consent process may need to emphasize 
additional or different factors in other types of genetic 
research. For example, obligations of the investigator to 
the  participants  differ  in  case-control  genomic  studies 
involving  unrelated  individuals  compared  with  family 
studies;  issues  surrounding  paternity,  for  example,  are 
not  directly  relevant  in  genomic  studies  of  unrelated 
individuals. Other questions that influence approaches to 
the  process  and  content  of  informed  consent  arise  in 
studies  exploring  genetic  information  obtained  from 
specific  genetic  variants  (such  as  single  nucleotide 
polymorphisms)  within  one  or  a  few  genes  compared 
with the whole genome. The creation of cell lines presents 
yet  another  different  set  of  issues,  including  the 
availability of an unlimited supply of genetic materials for 
an undefined period of time.
Overall, the design of genomic studies is perhaps the 
single most important factor that shapes the informed 
consent  document  and  process.  Beliefs  and  concerns 
associated with different types of genomic research vary 
among diverse population groups throughout the world. 
Therefore,  investigators  should  consider  carefully  the 
underlying  local  social  and  cultural  issues  that  are 
relevant to the design of genetic research when preparing 
documents and approaches to the consent process.
Data and biological sample sharing
The ability to combine and share large datasets generated 
by genomic projects has contributed significantly to the 
success  stories  enjoyed  by  the  genomic  scientific 
communities.  This  is  so  because  genomic  techniques 
such as the agnostic search of the genomes of individuals 
with disease compared with those without disease (called 
a genome-wide association study, GWAS) requires large 
numbers of study participants, usually in the thousands, 
to have adequate statistical power to find an association if 
one exists. These large datasets containing demographic, 
clinical and genetic information are usually deposited in 
data repositories such as dbGaP [22] with two main types 
of access requirements - fully open or controlled-access. 
The  fully  open  databases  (such  as  the  International 
HapMap  Project  and  the  1000  Genomes  Project  [19] 
generated from non-identifiable samples) can be directly 
accessed  and  downloaded  via  the  internet  by  anyone, 
without  any  restriction  [22].  Fully  open  databases  are 
anonymized  and  do  not  contain  clinical  (phenotype) 
information  except  gender  and  ethnicity/ancestry.  In 
contrast,  controlled-access  databases  such  as  GWASs 
may  contain  individual-level  demographic,  clinical  and 
genetic information; to access these controlled databases, 
investigators  are  required  to  obtain  permission  from  a 
data access committee. Although these types of database 
are coded and de-identified and therefore do not contain 
information that is traditionally used to identify indivi-
duals (such as name, address, and telephone and social 
security  number),  there  is  a  possibility  that  someone 
may develop ways to link information contained within 
them  to  individual  research  subjects.  Because  of  this 
possibility  and  government  policies  such  as  the  NIH 
GWAS  Policy  [23]  that  require  study  subjects  to  be 
informed that their phenotype and genotype data will 
be shared for research purposes, the informed consent 
documents for these studies are expected to be tailored 
to  contain  appropriate  language  to  enable  study 
participants  to  make  informed  decisions  regarding 
broad data sharing. Complications associated with the 
ability  to  withdraw  from  studies  will  become 
Table 1. Scientific, cultural, and social factors to consider in 
tailoring consent for genomic research
1  Study design (for example, disease versus non-disease studies; selected  
  genes versus whole genome)
2  Data and biological sample sharing requirements
3  Reporting study findings to participants
4  Cultural context of the study
5  Participant language and literacy
6  Participant knowledge of differences between research and clinical care
7  Potential for stigmatization of the study population
8  Inclusion of indigenous populations
9  Strength of economic, scientific and health infra-structures at study sites
10  Regulatory oversight
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of data, and this issue will need to be carefully assessed 
in approaches to the consent process [17,18].
International  collaborative  genomic  studies  involving 
data and sample sharing between high- and low-income 
countries call attention to additional ethical and social 
justice issues. For example, communicating information 
about the complex implications of sharing genetic and 
phenotypic information that may have implications for 
participants and their families must be addressed using 
language in the consent process that is both culturally 
meaningful and comprehensive. Moreover, as investiga-
tors involved in the MalariaGen project point out [24], it 
is  important  to  ensure  that  scientists  in  developing 
countries are not compromised because of the timing of 
the public release of data to the global scientific com-
munity. In this situation, open access to the data could 
place  researchers  from  developing  countries  at  a  dis-
advantage because they might not have the resources or 
capacity to respond as quickly to the data as scientists in 
developed countries. For this reason, MalariaGen investi-
gators  have  instituted  a  policy  that  includes  capacity 
building and training for scientists in low-income settings 
involved in their genomic research [24].
Traditionally, consent for genetic and genomic research 
has  addressed  the  issue  of  sample  sharing  by  asking 
participants  to  choose  whether  they  want  to  limit  the 
sample use to only the current study or disease under 
investigation, or be re-contacted for future studies, or if 
they  would  allow  future  use  of  samples  without  re-
contact.  However,  these  options  have  their  limitations 
and  raise  several  questions.  For  example,  it  may  be 
difficult for study participants to make judgments about 
future  use  because  it  is  hard  to  fully  comprehend  the 
implications of such decisions given the rapidly changing 
landscape of biomedical research in general, and genomic 
science in particular.
Reporting study results to participants
In  the  past,  most  genomic  research  projects  did  not 
report results back to participants. This decision was due, 
for the most part, to the uncertain clinical relevance of 
research findings. It is, however, becoming increasingly 
difficult to justify this position, especially in the context 
of  large-scale  medical  genotyping  and  sequencing 
research  studies  that  are  likely  to  generate  clinically 
relevant  genetic  information.  Examples  of  this  type  of 
genomic  study  include  ClinSeq  [20,21],  the  Coriell 
Personalized Medicine Collaborative [25], the Framing-
ham Heart Study [26] and the Jackson Heart Study [27]. 
However, communicating genomic results to participants 
requires tailored consent documents that carefully con-
sider  ethical  responsibilities  and  social  obligations  to 
participants and their relatives. To address these issues, 
the consent process and documents must contain clear 
and  appropriate  language  that  communicates  the  risks 
and  benefits  of  receiving  genetic  information  likely  to 
have varying levels of clinical and socio-economic rele-
vance to study subjects, their relatives and ethnic groups. 
Also,  the  ability  to  successfully  use  the  genetic  infor-
mation  to  inform  individual  and  public  health  will 
depend  on  many  cultural  and  socio-economic  factors. 
For example, low levels of literacy and access to care - 
especially  the  availability  of  genetic  counselors  in  a 
resource-poor environment - pose significant challenges 
to  investigators  who  may  have  good  intentions  about 
reporting results or are required by law to communicate 
genetic results to study participants.
An important consideration in genomic projects such 
as ClinSeq [20,21] is the discovery of clinically actionable 
results that are not part of the original aim of the study. 
For  example,  because  ClinSeq  is  conducting  complete 
sequencing of hundreds of cardiovascular genes, investi-
gators may discover genetic variants that have implica-
tions  for  non-cardiovascular  diseases,  such  as  cancer. 
What are ClinSeq investigators’ ethical and legal obliga-
tions to communicate incidental results to participants? 
How  should  this  information  be  communicated  to 
partici  pants?  Although  study  participants  may  want  to 
obtain  results,  what  can  or  should  they  do  with  the 
information  [28]?  Social  and  political  conundrums 
surrounding differential access to health care and health 
inequalities  between  population  groups  exacerbate 
challenges associated with disclosing both intended and 
unanticipated genetic findings. These and similar issues 
must  be  anticipated  and  adequately  addressed  in  the 
informed consent process and documents.
The  ClinSeq  consent  document  [20,21]  is  a  good 
example  of  tailoring  the  informed  consent  process  to 
explain issues related not only to communicating results - 
ranging from genetic variants known to cause disease to 
novel  and  uncertain  genetic  variants  with  no  known 
biological meaning - but also the potential psychological 
problems  if  participants  learn  they  are  carriers  of 
clinically relevant genetic variants that have implications 
for  themselves  and  family  members.  For  example,  the 
ClinSeq  consent  document  [21]  contains  specific 
language about the availability of genetic counselors to 
participants who may experience psychological problems 
as a result of knowing that they carry genetic variants 
that may increase their risk of disease. Current debates 
over  whether  or  not  to  report  these  findings,  and 
questions raised about procedures for reporting, reflect 
the complexity of the underlying concerns [28-32].
Cultural context
Beliefs  associated  with  illness  experiences,  inherited 
diseases  and  biomedical  and  genetic  research  are 
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implications for the implementation of genomic studies 
and  the  design  of  consent  processes  [33].  Participants 
may have personal, religious or ethical beliefs that limit 
the types of medical tests, treatments or procedures they 
would  want  to  receive  as  part  of  study  participation 
(vaccination  and  blood  transfusion,  for  example).  In 
some  cultural  settings,  customs  and  traditions  also 
influence beliefs about who has the authority to provide 
informed consent for research participation [34-37]. For 
example,  in  our  genomic  research  on  podoconiosis  in 
Southern  Ethiopia  [38],  we  found  that  participants 
wanted to discuss the study with family members before 
giving  consent.  Similarly,  in  our  international  project 
investigating  factors  influencing  informed  consent  for 
genetic  research  on  hypertension  in  a  rural  town  in 
Nigeria  [39],  we  found  that  nearly  half  of  the  married 
women  reported  that  they  needed  to  talk  with  their 
husbands before giving their consent.
Language and literacy
The language spoken by study participants and literacy 
levels  of  study  populations  are  essential  factors  to 
consider in developing tailored approaches to informed 
consent. Although it may seem obvious for investigators 
to develop linguistically appropriate consent documents 
using clear and simple language, the use of complicated 
biomedical  and  scientific  language,  and  lengthy  and 
cumbersome consent forms, continue to be challenging 
for  participants,  particularly  in  low-income  settings 
around the world [40,41]. Comprehension of information 
provided  in  consent  forms  and  consent  discussions  is 
foundational  to  voluntary  participation.  How  much 
infor  mation  is  necessary  -  and  in  what  format  -  for 
individuals to understand the implications of joining a 
genomic study? These are important issues to consider in 
tailoring  informed  consent  processes  for  genetic  and 
genomic  research.  For  example,  in  our  podoconiosis 
project [38], we observed that the majority of participants 
did  not  understand  that  information  in  the  informed 
consent document and discussion was provided to enable 
them to make a decision about participating in the study. 
Instead,  participants  thought  the  information  was 
provided as a form of health education.
Participant knowledge of differences between research 
and clinical care
A thorny problem for all scientific and medical researchers, 
not  just  those  involved  in  genomic  studies,  concerns 
misunderstandings about the difference between medical 
testing  or  treatment  and  medical  research.  Research 
projects often include procedures to classify the health 
(disease) status of study participants. These procedures 
could  range  from  basic  clinic  activities  (such  as 
com  pleting  questionnaires,  measuring  blood  pressure 
and drawing blood) to more involved procedures, such as 
echocardiograms  and  computer  tomography.  There  is 
potential  for  therapeutic  misconception,  and  this  is  a 
serious challenge for investigators. The important issue 
here is that, in some studies, diagnostic services could 
represent clinical services for participants; this may be 
both  an  incentive  and  a  source  of  confusion  for 
individuals, particularly in settings in which medical care 
is limited or unavailable. The Framingham Heart Study 
[26], the Jackson Heart Study [27], the Coriell Persona-
lized  Medicine  Collaborative  Study  [25]  and  ClinSeq 
[20,21] are all examples of projects in which participants 
derive direct benefits because they will undergo testing 
that could lead to clinically relevant information such as 
disease  diagnosis.  In  contrast,  studies  like  the 
International HapMap Project [19] and our genetics of 
podoconiosis study in Ethiopia [38] do not provide direct 
clinical benefits to participants. Regardless of direct or 
indirect  study  benefits,  it  is  important  to  develop 
linguistically  and  culturally  meaningful  approaches  to 
informed consent to ensure that participants know they 
are  involved  in  a  genetic  research  project  and  not 
undergoing tests or procedures for clinical care.
Potential for stigmatization of study populations
A tailored informed consent process should consider the 
social  meaning  that  study  participants  attach  to  the 
disease  under  investigation.  Diseases  such  as  hyper-
tension or diabetes may be viewed very differently from 
potentially  stigmatizing  conditions  such  as  mental 
illnesses or physically identifiable diseases. Podoconiosis, 
for example, is a disease that results in the swelling of the 
lower legs among people exposed to red clay soil. It is a 
stigmatizing health condition in endemic areas such as 
Ethiopia  because  of  the  widely  held  beliefs  that  the 
disease runs in families and is untreatable. We recently 
demonstrated  [42]  that  the  social  stigma  attached  to 
podoconiosis affected the process of obtaining informed 
consent for genetic research on this disease in Southern 
Ethiopia;  we  found  that  participants  were  afraid  of 
participating in a genetic study because they were fearful 
that  it  might  aggravate  stigmatization  by  exposing  the 
familial  nature  of  the  disease.  Investigators  have  a 
responsibility to identify additional risks associated with 
genetic research participation for stigmatized individuals 
or  groups  when  developing  approaches  for  informed 
consent,  and  should  also  use  culturally  appropriate 
strategies to protect marginalized groups [43,44]. Before 
initiating a study, researchers should consider what confi-
dentiality,  privacy  and  ‘secrecy’  mean  to  study  partici-
pants  who  may  bear  the  burden  of  stigmatization  or 
discrimination, and they should apply this knowledge in 
developing the consent process.
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Genetic investigators working with indigenous popula  tions 
face unique challenges. For example, some researchers and 
industries have been accused of ‘biopiracy’ by engaging in 
research activities that disrespect or take unfair advantage 
of ownership of indigenous biological resources. Biopiracy 
often leads to inadequate compensation to the people - or 
nations - who provided the biological samples. Accusations 
of biopiracy, whether or not the allegations are true, can 
affect  both  the  willingness  of  indigenous  groups  to 
participate in research and the enthusiasm of scientists to 
approach indigenous communities about participating in 
genomic  research.  It  is  therefore  important  that  issues 
surrounding biopiracy are addressed before the initiation 
of  sample  and  data  collection.  It  is  also  essential  that 
intellectual property rights and the development of patents 
are  addressed  before  initiating  genomic  research  with 
indigenous  groups  [45].  Benefits  derived  from  genetic 
research  include  financial  gain  associated  with  product 
development and patents based on study results, and this 
has  direct  implications  for  future  obligations  of  investi-
gators at the completion of a project [46]. For example, in 
2000, AutoGen, an Australian biotechnology firm, signed 
an  agreement  with  the  Ministry  of  Health  in  Tonga  to 
estab  lish a private genetic database to study genes involved 
in  diabetes,  obesity  and  other  diseases  [47].  Although 
ownership of the DNA samples would be the property of 
Tonga,  AutoGen  would  retain  exclusive  rights  to  the 
database and could use it for research that would lead to 
drug  development.  In  return,  AutoGen  would  provide 
Tonga’s Ministry of Health with annual research funding 
and royalties from commercialized products based on gene 
discoveries;  pharmaceutical  drugs  developed  would  be 
provided for free to the Ministry of Health. Serious ethical 
questions were raised over issues associated with privacy, 
ownership and the commercialization of genetic material 
in a resource-poor setting such as Tonga, which is ruled by 
an island monarchy. In 2002, AutoGen indicated that they 
would not pursue the development of a genetic database in 
Tonga [47-49].
Another important issue in the context of working with 
indigenous groups concerns the need, in some cases, for 
community  approval  or  ‘consent’,  depending  on  local 
governance  and  political  authority  [50].  Examples  of 
policies for ethical conduct in research that demonstrate 
respect  for  the  concerns  and  rights  of  indigenous 
populations include guidance for the First Nation people 
in Canada [51,52], American Indian Nations in the USA 
[53],  aboriginal  communities  in  Australia  [54]  and  the 
Maori of New Zealand [55].
Socio-economic and health infrastructure
The  strength  of  economic,  scientific  and  health  infra-
structures at study sites highlights the need for genomic 
investigators to pay careful attention to these issues as 
part of informed consent requirements. In resource-poor 
environments and low-income settings, researchers may 
have  considerable  power  to  influence  the  voluntary 
participation of individuals and communities that they 
hope to involve in their studies. For example, physicians 
and  other  health  professionals  conducting  a  research 
project may also be responsible for the care of potential 
participants. Also, in some cases, the opportunities for 
economic  support  and  capacity  building  that  genetic 
researchers  may  be  able  to  provide  can  influence  the 
willingness  of  local  investigators  to  sponsor  the  study. 
Moreover,  the  effect  of  unequal  power  between 
researchers from resource-rich settings and host sponsors 
at resource-poor sites may influence local research ethics 
committees  to  approve  studies  and  provide  regulatory 
oversight. Questions surrounding the potential for undue 
influence and its ability to affect voluntary participation 
must be taken into account. Collaborative partnerships 
that endure over time contribute to a foundation of trust, 
cooperation  and  capacity  building;  these  partnerships 
help  diminish  the  potential  for  undue  influence  at  all 
levels [56].
Regulatory oversight
Regulatory  governance  and  oversight  for  genetic  and 
genomic research have direct implications for the pre-
para  tion of informed consent documents. For example, 
the  implementation  of  the  HapMap  Project  in  Nigeria 
required approval from three institutional review boards 
(IRBs)  [19].  Although  the  informed  consent  document 
for  the  International  HapMap  Project  underwent 
extensive review and revision at the NIH before initiating 
the study, two of the IRBs - one in the US and the other at 
the  Nigerian  site  -  raised  questions  about  the  consent 
document  and  requested  revisions.  Addressing  the 
bureaucratic exigencies of IRBs resulted in the delay of 
the  project  [19].  Another  example  of  the  impact  of 
regulatory requirements for informed consent concerns 
the question of whether or not de-identified samples are 
considered to be ‘human subjects’; guidance on this issue 
will  affect  the  use  of  samples  in  future  research  [18]. 
Moreover,  in  multi-national  genetic  research  projects, 
national regulatory guidelines concerning the definition 
of human subjects may be in conflict.
Conclusions
Social and ethical issues associated with the process of 
informed consent for genomic research are challenging 
for  research  participants,  investigators  and  policy 
makers. We agree with other investigators [17,18] who 
recognize that policy and guidelines need to be revised 
quickly in response to the continually evolving enterprise 
of genomic research as new knowledge is generated and 
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the development of new policies will affect the develop-
ment  of  informed  consent  documents.  Moreover,  it  is 
reasonable  to  expect  that  as  researchers  continue  to 
improve approaches to consent - including clear descrip-
tions of the risks and benefits - individuals may be more 
likely to donate DNA samples for genomic research or, 
minimally,  may  be  better  informed  to  make  decisions 
regarding participation in genomic studies.
There is a great need for continuing efforts to increase 
public knowledge about genomic research. As individuals 
and  communities  from  diverse  social  backgrounds 
become more aware of genomic research and the poten-
tial role of genetics in contributing to health outcomes, 
the  public  will  hopefully  be  more  informed  about  the 
implications  of  genomic  research  for  personal  medical 
care, public health and more broadly the public represen-
tation  of  diverse  population  groups  based  on  genetic 
findings. This knowledge should reinforce the ability of 
potential  participants  to  make  informed  choices  about 
joining  a  genetic  study.  There  are  complicated  issues 
underlying public trust in medicine as well as scientific 
and genetic research that must be addressed. Innovative 
strategies for public education and community engage-
ment  should  take  into  account  cultural  settings  and 
historical experiences that have contributed to distrust in 
the past.
Finally,  there  is  a  critical  need  for  further  empirical 
research  on  innovative  approaches  to  the  process  of 
informed  consent  for  genomic  research  that  take  into 
account scientific, social and cultural factors. Examples 
of such studies might include randomized trials testing 
the effectiveness of tailored models of informed consent 
for different types of genomic studies with socially and 
ethnically  diverse  populations.  Research  exploring  the 
use of simplified consent documents for genetic research, 
along  with  pre-consent  educational  sessions  and  the 
provision  of  educational  materials,  are  another  avenue 
for research. Studies might also examine the effects of 
using multiple media - such as video tapes, written docu-
ments and group or individual educational sessions - on 
comprehension of study goals, risks, benefits and future 
implications of participating in a genetic study.
We are at an important juncture in conducting trans-
lational genomic research that has potential for clinical 
and  public  health  applications.  Our  challenge  is  to 
develop approaches to the informed consent process that 
enhance  understanding  of  the  nature,  goals  and 
implications  of  particular  studies  and  simultaneously 
address  the  pragmatic  constraints  of  implementing 
genomic research and reporting study results.
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